Apogee Therapeutics, Inc. Common Stock Market Cap ($8.40 Billion)
Market Cap & Net Worth: Apogee Therapeutics, Inc. Common Stock (APGE)
Apogee Therapeutics, Inc. Common Stock market cap. Apogee Therapeutics, Inc. Common Stock (NASDAQ:APGE) has a market capitalization of $8.40 Billion ($8.40 Billion) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2464 globally and #915 in its home market, demonstrating a 0.16% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Apogee Therapeutics, Inc. Common Stock's stock price $135.07 by its total outstanding shares 62201093 (62.20 Million).
Apogee Therapeutics, Inc. Common Stock Market Cap History (2023–2026)
Apogee Therapeutics, Inc. Common Stock market cap history from 2023 to 2026. Data shows growth from $1.74 Billion to $8.40 Billion (93.39% CAGR). Check APGE stock price and chart for real-time trading data and today's change.
Index Memberships
Apogee Therapeutics, Inc. Common Stock is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.32% | #56 of 976 |
|
NASDAQ Composite
IXIC
|
$40.85 Trillion | 0.02% | #288 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.46% | #39 of 263 |
Weight: Apogee Therapeutics, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Apogee Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Apogee Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see APGE operating cash flow for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of APGE by Market Capitalization
Companies near Apogee Therapeutics, Inc. Common Stock in the global market cap rankings as of October 31, 2026. See Apogee Therapeutics, Inc. Common Stock (APGE) net asset quality to understand what proportion of total assets are financed by equity.
Key companies related to Apogee Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of Apogee Therapeutics, Inc. Common Stock (2023–2026)
Market capitalization of Apogee Therapeutics, Inc. Common Stock from 2023 to today. Between 2023 and today, Apogee Therapeutics, Inc. Common Stock's market cap moved from $1.74 Billion to $ 8.40 Billion, with a yearly change of 93.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.40 Billion | +78.95% |
| 2025 | $4.69 Billion | +66.62% |
| 2024 | $2.82 Billion | +62.13% |
| 2023 | $1.74 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Apogee Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.40 Billion USD |
| MoneyControl | $8.40 Billion USD |
| MarketWatch | $8.40 Billion USD |
| marketcap.company | $8.40 Billion USD |
| Reuters | $8.40 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chr… Read more